The STEP 1 trial extension The most cited data comes from the STEP 1 trial extension, published in Diabetes, Obesity and Metabolism
Storage and Handling Keep unopened lyophilised material at approximately -20C for long-term storage or 2-8C for short-term laboratory storage
While Semaglutide may lead to a reduction in stomach size, it is not a permanent change
Those who want to lose large amounts of weight may choose to start on semaglutide for insurance-coverage purposes, then can switch over to tirzepatide if weight loss stalls
The key insights of the report have been presented through the frameworks of SWOT and Porters Five Forces Analysis
23 These symptoms can be severe in some patients, resulting in a pause of dose escalation, and if intolerable GI symptoms continue, a dose adjustment to the previous lower dose or a switch to an alternative GLP-1 RA should be considered